Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

STX-1150

Phase 1Small molecule

MMonash University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholesterolRecruiting

CholesterolPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Cholesterol

NCT07428473

Clinical

Trials by Indication[1]

Cholesterol1 trial

A Phase 1 Open-Label Single Ascending Dose (Part 1) and Single or Multi-Dose Expansion (Part 2) Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)

Recruiting·MMonash University·Phase 1·NCT07428473·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for STX-1150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — STX-1150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for STX-1150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Monash University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMonash University

Related News